Related Experiment Video
Updated: Jun 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled
F Patti1, M P Amato, S Bastianello
1Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital Catania, Catania, Italy. patti@unict.it
Abstract:
The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNbeta-1a) on cognition in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Patients aged 18-50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Alzheimer's Disease: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Multiple Sclerosis l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids